Cynata Therapeutics has received a Positive Opinion from the European Medicines Agency’s Paediatric Committee (PDCO) on its ...

HealthDay News — Having a preexisting autoimmune disease is an independent risk factor for poor outcomes with myelodysplastic syndrome (MDS), according to a study published in the June issue of ...

Dubbed “the next frontier of cancer prevention and care,” the microbiome appears to be especially critical when it comes to ...

Stem cell transplantation is the most cost-effective option for long-term care of sickle cell disease in adults when compared ...

Many modern cancer treatments, including immunotherapy, depend on activating killer T cells to recognise and destroy tumours.

Scientists have uncovered a surprising new way the immune system fights cancer, overturning a core belief that has guided ...

Hansa will apply to the EMA to convert Idefrix’s conditional approval into full marketing authorisation.

Stem cell transplantation is the most cost-effective option for long-term care of sickle cell disease in adults when compared ...

Stem cell transplantation is the most cost-effective option for long-term care of sickle cell disease in adults when compared with gene therapy and standard of care treatment, according to new ...

FT819 off-the-shelf CAR T-cell therapy product candidate continues to broaden patient access with 21 SLE patients now treated ...

Review Highlights Emerging Engineering Strategies Including Combination Approaches Designed to Enhance Anti-Tumor Activity, ...